News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

PeptiMed Signs Agreement With National Cancer Institute to Assess Safety of HelpTM Drug Delivery Nanoparticle Formulations



6/23/2014 11:43:13 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

MADISON, Wisc.--(BUSINESS WIRE)--PeptiMed announced today that under a Material Transfer Agreement it will collaborate with the National Cancer Institute’s (NCI) Nanotechnology Characterization Laboratory (NCL), located at the Frederick National Laboratory of Cancer Research in Frederick, MD. Under the terms of the Agreement, PeptiMed will provide the NCL with nanocomplex consisting of its proprietary siRNA and patented elastin-like polypeptides (ELPs), and NCL personnel will measure material properties indicative of safety and efficacy for potential future dosing in the clinic.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES